NCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Conditions

• Solid Tumors
• Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	INCA036873	Intravenously (IV)

Timeline

• Start date: 2026-01-08
• Primary completion: 2028-08-18
• Completion: 2028-08-18
• First posted: 2025-09-29
• Last updated: 2026-04-14

Locations

22 sites across 5 countries: United States, Australia, Belgium, Denmark, Italy

Regulatory

• FDA-regulated drug study